Cardiomyocyte-specific Estrogen Receptor Alpha Increases Angiogenesis, Lymphangiogenesis and Reduces Fibrosis in the Female Mouse Heart Post-Myocardial Infarction

Shokoufeh Mahmoodzadeh1,*, Joachim Leber1, Xiang Zhang1,2, Frédéric Jaisser3, Smail Messaoudi1, Ingo Morano4, Priscilla A Furth5, Elke Dworzatzek1 and Vera Regitz-Zagrosek1

1Institute of Gender in Medicine and Center for Cardiovascular Research, Charité Universitätsmedizin, Berlin, Germany
2Department of Cardiology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China
3Inserm, U872, Paris, France
4Max-Delbrueck-Center for Molecular Medicine, Berlin, Germany
5Departments of Oncology and Medicine and the Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA

*authors contributed equally to this work

Abstract

Experimental studies showed that 17β-estradiol (E2) and activated Estrogen Receptors (ER) protect the heart from ischemic injury. However, the underlying molecular mechanisms are not well understood. To investigate the role of ER-alpha (ERα) in cardiomyocytes in the setting of myocardial ischemia, we generated transgenic mice with cardiomyocyte-specific overexpression of ERα (ERα-OE) and subjected them to Myocardial Infarction (MI). At the basal level, female and male ERα-OE mice showed increased Left Ventricular (LV) mass, LV volume and cardiomyocyte length. Two weeks after MI, LV volume was significantly increased and LV wall thickness decreased in female and male WT-mice and male ERα-OE, but not in female ERα-OE mice. ERα-OE enhanced expression of angiogenesis and lymphangiogenesis markers (Vegf, Lyve-1), and neovascularization in the peri-infarct area in both sexes. However, attenuated level of fibrosis and higher phosphorylation of JNK signaling pathway could be detected only in female ERα-OE after MI. In conclusion, our study indicates that ERα protects female mouse cardiomyocytes from the sequelae of ischemia through induction of neovascularization in a paracrine fashion and impaired fibrosis, which together may contribute to the attenuation of cardiac remodelling.

Keywords: Estrogen receptor alpha; Myocardial infarction; Angiogenesis; Lymphangiogenesis; Cardiac fibrosis

Abbreviations: CD31: Platelet/endothelial cell adhesion molecule-1 (Pecam-1); Col I, Col III: Collagen type I and III; CVD: Cardiovascular Diseases; E2: 17β-estradiol, Estrogen; ERα: Estrogen receptor alpha (Est-1), ERα-OE: Cardiomyocyte-specific Overexpression of ERα; GAPDH: Glyceraldehyde 3-Phosphate Dehydrogenase; H&E staining: Hematoxylin-Eosin staining; Hprt: Hypoxanthine Phosphoribosyltransferase; JNK: Mitogen-activated protein kinase c-jun N-terminal Kinase; K17N: Mitogen-activated protein kinase c-jun N-terminal Kinase; LAD: Left Anterior Descending coronary artery; LV: Left Ventricle; LVM/TL: LV Mass to Tibia Length; Lyve-1: Lymphatic vessel endothelial hyaluronan receptor-1; Nppa: Myocardial Hypertrophy; Nppb: Myocardial Infarction; Myh6, Myh7: Myosin heavy chain 6 and 7; Pecam-1: Platelet/endothelial cell adhesion molecule-1; Pgf: Vascular endothelial growth factor

Introduction

The incidence of Cardiovascular Diseases (CVD) and its associated mortality is lower in premenopausal women compared to aged-matched men, but increases rapidly after menopause and reaches similar level as in men (for review see [1]). These data suggest that 17β-estradiol (estrogen, E2) prevents CVD in premenopausal women and contributes to the observed sex differences. Accordingly, several clinical studies and experimental animal settings showed that E2 deficiency has been associated with an increased risk of mortality after cardiac injury, which was improved by E2 supplementation [2-4]. Experimentally, administration of E2 reduced infarct size and cardiomyocyte apoptosis [5-7], improved myocardial recovery and viability after Ischemia-Reperfusion (I/R) injury in different animal models [8-14]. The treatment with Estrogen Receptor (ER) antagonist ICI 182 780 reversed the E2-induced effects indicating that these effects are mediated by ER [8]. However, E2 and its receptor effects on the heart and vasculature are incompletely understood, and require a better basic understanding of the underlying mechanisms.

ER-alpha (ERα) is one of the known ER which mediates, at least partly, the beneficial effects of E2 on the heart during stress, in a genomic or non-genomic manner [15]. ERα is expressed and localized in different cardiac cell types of humans and rodents, such as cardiomyocytes, fibroblasts and endothelial cells [16-20]. Increased expression of ERα could be detected in the heart of patients with aortic stenosis and dilated cardiomyopathy, most likely as a compensatory mechanism [18,19]. The absence of ERα is associated with the increased presence of atherosclerotic plaque in humans, especially in premenopausal women [21,22]. In line with these findings, it has been demonstrated that ERα-knockout (ERKO) mouse hearts subjected to I/R had fewer viable cardiomyocytes, decreased coronary flow rate, marked myocardial edema, more prominent mitochondria damage, and decreased functional recovery of contractility and compliance.

*Corresponding author: Shokoufeh Mahmoodzadeh, Institute of Gender in Medicine, Center for Cardiovascular Research, Hessische Str. 3-4, 10115 Berlin, Germany, Tel: +49 (0)30 450 525 287; Fax: +49 (0)30 450 525 943; E-mail: s.mahmoodzadeh@charite.de

Received December 29, 2013; Accepted January 27, 2014; Published January 30, 2014

Citation: Mahmoodzadeh S, Leber J, Zhang X, Jaisser F, Messaoudi S, et al. (2014) Cardiomyocyte-specific Estrogen Receptor Alpha Increases Angiogenesis, Lymphangiogenesis and Reduces Fibrosis in the Female Mouse Heart Post-Myocardial Infarction. J Cell Sci Ther 5: 153. doi:10.4172/2157-7013.1000153

Copyright: © 2014 Mahmoodzadeh S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
compared with WT-mice [23,24]. By contrast, administration of an ERα-selective agonist during Myocardial Infarction (MI) and the following phenomenon of I/R injury results in the reduction of infarct size, neutrophil infiltration, oxidant stress, necrosis, and improvement of myocardial recovery [9,10,25-27]. These data suggest that ERα contributes to myocardial salvage after injury, and it is of critical importance to understand the relative role of this receptor in the heart. However, the activity of ERα is tightly regulated in a cell specific manner through complex processes which are still not fully understood. Since cardiomyocytes are more susceptible to ischemia than other cardiac cell types and their survival determines the outcome after myocardial ischemia [28], we aimed to analyze the specific role of ERα in cardiomyocytes during ischemia. We therefore generated a transgenic mouse model with a cardiomyocyte-specific ERα overexpression (ERα-OE) and subjected mice of both sexes to MI. We chose a gain of function approach, since it allows us to study the in vivo potential role of activation of ERα in cardiomyocytes, which is not feasible in a loss of function approach. This study helps to elucidate the protective potential of ERα in cardiomyocytes under ischemic conditions. Targeted activation of ERα to enhance cardioprotective mechanisms could provide novel therapeutic options for the diseased hearts.

Materials and Methods

Transgenic animals

Inducible double transgenic mice with cardiomyocyte-specific ERα overexpression (ERα-OE) were generated through mating of transgenic mouse with ERα overexpression (ERα-OE) and subjected mice of both sexes to MI. We chose a gain of function approach, since it allows us to study the in vivo potential role of activation of ERα in cardiomyocytes, which is not feasible in a loss of function approach. This study helps to elucidate the protective potential of ERα in cardiomyocytes under ischemic conditions. Targeted activation of ERα to enhance cardioprotective mechanisms could provide novel therapeutic options for the diseased hearts.

Myocardial infarction model

MI was induced in Female (F) and Male (M) mice at 12 weeks of age, by permanent left anterior descending Coronary Artery (LAD) ligation. Mice were anesthetized with ketamine hydrochloride (80 mg/kg) and 35 µg ketamine. Hearts were rapidly removed and perfused with cold saline, followed by intraperitoneal injection of 8 µg xylazine and 35 µg ketamine. Hearts were rapidly removed and perfused with a low Ca2+, collagenase bicarbonate buffer solution (36°C, pH 7.4) for 10 min. Subsequently, the ventricles were minced. After several wash steps, isolated cardiomyocytes were finally resuspended in M199 medium (Sigma, Germany) supplemented with 0.2% bovine serum albumin, 5% fetal calf serum, 5 mmol/l creatine, 5 mmol/l taurine, 2 mmol/l carnitine, 10 µmol/l cytosine-D-arabinofuranoside, and antibiotics. Cardiomyocytes were seeded in 2-well chamber slides (Nunc, Wiesbaden-Schierstein, Germany) and cultured for 4 h in M199 medium before measurement of their length and width.

Cell morphology

The individual length and width of the cardiomyocytes were determined on micrographs captured by Axiolab 40 CFL microscope (using objective: Achromplan 10x/0.25 Ph1 W 0.8) and digitalized by AxioCam MR3 camera. Ten micrographs per sample were randomly taken, and 100 to 300 rod-shaped myocytes were measured per sex and genotype. Length and width of cardiomyocytes were determined at the widest point of each myocyte using the software program “AxioVision Release 4.8” (Zeiss).

Gene expression analysis

Total RNA isolation and quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) was conducted as previously described [31]. Quantification of expression levels of the mouse ERα (Esr1), atrial natriuretic peptide (Nppa), brain natriuretic peptide (Nppb), myosin heavy chain 6 and 7 (Myh6, Myh7), platelet/endothelial cell adhesion molecule-1 (Pecam-1 or CD-31), vascular endothelial growth factor (Vegf), lymphatic vessel endothelial hyaluronan receptor-1 (Lyve-1), collagen type I and III (Col I and Col III) was performed by real time PCR, using SYBRGreen (Bio-Rad Laboratories, Hercules, CA, USA). The housekeeping gene Hypoxanthine Phosphoribosyltransferase (Hprt) was used to normalize the results. Primer sequences used for amplification are listed in (Table S1).

Western blot analysis

Western blot analyses were performed using whole LV tissues isolated from female and male ERα-OE mice (n ≥ 8) or WT-mice (n ≥ 8) as previously described [19]. Briefly, for each sample, 25 µg of protein was loaded into a 10% polyacrylamide gel, electrophoresed, and transferred to a nitrocellulose membrane. Western blot analyses were
performed using a standard protocol with specific primary antibodies against ERα (G-20, Santa Cruz), phospho-ERα (pERα (serin 118)-R; Santa Cruz), mitogen-activated protein kinase c-jun N-terminal kinase JNK1/3 (C-17, Santa Cruz), p-JNK (G-7, Santa Cruz), GAPDH (clone 6C5, Millipore) and donkey anti-mouse IgG or donkey anti-rabbit IgG secondary antibody (Jackson Immuno Research Laboratories). Specific bands were visualized using ECL™ detection kit (GE Healthcare). Band intensities were quantified with ImageJ software 1.37V.

**Histological analysis**

After dissection, the transverse midsection of the LV was immediately fixed in 4% formaldehyde for 24 h and paraffin-embedded for sectioning. Serial tissue sections (3 μm) were cut and routinely stained with Hematoxylin-Eosin (H&E) and visualized by light microscopy. To analyze the changes in fibrotic areas, LV sections were stained with Sirius red to determine collagen deposition. The fibrosis area was measured and calculated as the percent of the area of fibrosis to entire cross-sectional area of LV by using the Media Cybernetics Image Pro PLUS software (Bethesda, MD).

**Immunofluorescence analysis**

Double-labeling immunofluorescence histochemistry was performed as previously described [18]. Briefly, after paraffin-embedded LV sections (3 μm) were deparaffinized with Neoclear (Merck, Germany) and rehydrated to PBS, the sections were subjected to heat-mediated antigen retrieval by pressure cooking in 10 mM citric acid buffer, pH 6.0. After cooling down to room temperature for 20 min, and 1 h of blocking in 1%BSA-PBST (1xPBS+0.2% Tween) at room temperature, sections were incubated with primary antibodies against CD31 or LYVE-1 (1X-13 SC-80170, 1:50 dilution) overnight at 4°C. After washing, sections were incubated with secondary FITC-conjugated anti-rabbit IgG (Jackson ImmunoResearch Laboratories) and Cy3-conjugated anti-rat IgG (Jackson ImmunoResearch Laboratories) both at a dilution of 1:100 in 0.1% BSA-PBST, for 1 h at RT. Nuclei were stained with 6-diamidino-2-phenylindole (DAPI). Finally, sections were mounted with VectaShield H-1000 (Linaris) and viewed on an upright fluorescence microscope (Olympus BX61). Negative controls included sections in which either the primary antibody or secondary antibody or both were omitted. In these sections no signals for CD31 and LYVE-1 were detectable. Quantification of immunoreactivity by pixel intensity was analyzed by Image Pro PLUS software (Bethesda, MD). The ratio of area of CD31 or LYVE-1 expressing vessels to whole LV cross-sectional area was calculated.

For detection of ERα in the LV sections of WT and ERα-OE mice, following antibodies were used: primary antibody anti-ERα (G20, Santa Cruz), secondary antibody FITC conjugated goat anti-rabbit (Jackson Laboratory). Confocal images were acquired using a Leica TCS-SPE spectral laser scanning microscope, and images were processed by Leica Application Suite AF software (version 1.8.0).

**Statistics**

All data are presented as mean ± standard error of the means (SEM). Statistical analysis was performed using One-way ANOVA followed by Bonferroni’s test to compare multiple groups, and two-tailed Student’s t-test to compare the mean of two groups. Kaplan–Meier curves were created to illustrate cumulative mortality after MI, and statistical assessment was performed by the log-rank test. Statistical analyses were performed using software Graphpad Prism 5.01. Differences with p ≤ 0.05 were considered significant.

**Results**

**Characterization of cardiomyocyte-specific ERα overexpressing transgenic mice**

We first evaluated the phenotype of a transgenic mouse model with a constitutive cardiomyocyte-specific overexpression of ERα (ERα-OE). Overexpression of ERα was detected in the LV tissues of ERα-OE mice compared to WT-mice using Western Blotting and immunohistochemistry (Figure 1). We found a 10-13 fold increase in the expression of ERα transgene 66 kDa isoform in LV-tissues of female and male ERα-OE mice (Figure 1A). No sex-differences in ERα expression levels were detected. Comparison of ERα expression levels in the LV, kidney, liver, uterus and lung of 12 week-old ERα-OE mice showed that the ERα overexpression was restricted to the heart (Figure 1B). ERα-OE hearts showed a significant increase (3.5-5.0 fold) in the phosphorylation level of ERα compared to WT-mice without sex-differences (Figure 1C). Immunofluorescence data demonstrated a more intense ERα signal in the LV of ERα-OE mice with the strongest signal in the nuclei of cardiomyocytes (Figure 1D).

**ERα-overexpression promotes cardiac hypertrophy in the basal state in both sexes**

Ratio of LV mass to tibia length (LVM/TL) was significantly increased in ERα-OE compared to WT-mice in both sexes, demonstrating the development of Myocardial Hypertrophy (MH) in ERα-OE mice (table 1). This was due to an increase in ventricular diastolic and systolic volumes, but not wall thickness in both sexes (table 1). On microscopic examination of isolated cardiomyocytes, female and male ERα-OE displayed a significant increase in cardiomyocyte length, but not in cardiomyocyte width compared with WT-mice (Figures 2A-2E). In line with these data, expression of hypertrophic marker genes atrial natriuretic peptide (Nppa) and brain natriuretic peptide (Nppb) was significantly increased in the LV of ERα-OE mice (Figures 2D and 2E). The ratio of myosin heavy chain 7 and 6 (Myh7/Myh6) was shifted towards higher expression of the slower Myh7 isoform (Figure 2F). These findings overall indicate that cardiomyocyte-specific ERα-OE leads to the spontaneous development of cardiac hypertrophy in both sexes.

**Survival Analysis after myocardial infarction**

To investigate the in-vivo potential of ERα overexpression under pathological conditions, MI was induced. The mortality was high within the first 24 h after MI among all groups without significant differences between groups. However, after this acute phase, females ERα-OE survived 100%, suggesting that ERα overexpression in female hearts increased survival after MI, which was not observed in males (Figure 3). Infarct size was similar in both sexes after MI (Table 1). In mice overexpressing ERα, infarct size was slightly decreased compared to WT mice (Table 1) however the difference was not statistically significant.

**ERα improves myocardial adaptation after myocardial infarction in females**

Similar to female and male WT-mice, male ERα-OE mice showed significant increase in LV volumes and decrease in wall thickness two weeks after MI. In contrast, female ERα-OE hearts showed no significant changes in these parameters (Table 1). Cardiac functional parameters, such as stroke volume, cardiac output and heart rate, were not significantly different between the groups (Table 1). Although both
ERα enhances cardiac angiogenesis and lymphangiogenesis after myocardial infarction in both sexes

In paraffin-embedded, Hematoxylin-Eosin-stained (H&E) heart sections from female and male ERα-OE mice, we observed increased occurrence of vascular-like structures predominantly in the peri-infarct area. This was found to a lesser extent in the WT-mice of both sexes (Figures 4A and 4B). To assess the nature of these vessel-like structures, we performed immunofluorescence double staining experiments using antibodies against CD-31 (PECAM-1 or) for the staining of blood vessel, and against LYVE-1 for the staining of lymphatic vessels. Very few CD31 and LYVE-1 positive signals were found in the hearts of WT and ERα-OE sham mice (Figures 4C, 4D, 4G and 4H). After MI, predominately in the peri-infarct areas and to the lesser extent in the infarct areas, the signals for CD31 and LYVE-1 were significantly increased in both female and male ERα-OE mice hearts compared to their respective sham-operated and to WT controls (Figures 4E, 4F, 4G and 4H). Additionally, areas of CD31- and LYVE-1 expressing vessels were significantly greater in both female and male ERα-OE mice hearts than those in WT-mice hearts after MI (Figures 4E-4H). Consistently, the expression of Vegf, a key inducer of angiogenesis, and Lyve-1 were significantly increased in tissues obtained from the infarct and peri-infarct area of female and male ERα-OE mice hearts compared with WT-mice (Figures 4I and 4J). Taken together, ERα-overexpression in
**Figure 2:** ERα-overexpression promotes cardiac hypertrophy in the basal state in both sexes. A: Representative micrographs of single cardiomyocytes of WT- and ERα-OE mice (40x magnification, scale bar 100µm). B-C: Quantification of diastolic cell length and cardiomyocytes width. Compared to WT, cardiomyocytes isolated from female and male ERα-OE displayed a significant increase in diastolic cell length, but no changes in cell width at the basal level. Data are given as mean ± SEM for 100 to 300 cells per group. § for the genotype effect (ERα-OE vs. WT, p<0.001); * for females vs. males (p<0.001). D-F: Expression analysis of hypertrophy markers. D: Nppa, E: Nppb, and F: the ratio of Myh7/Myh6 expression in the LV tissues of female and male ERα-OE mice compared with WT-mice. §for the genotype effect (ERα-OE vs. WT, females: p<0.01, p<0.01, p<0.01; males: p<0.001, p<0.001, p<0.01, for each gene). * for MI effect (MI vs. sham, females: p<0.05, p<0.001, p<0.01, males: p<0.05, p<0.01, p<0.01, for each gene). n≥10.

**Figure 3:** Comparison of survival curves from female and male ERα-OE and WT mice 2 weeks after MI. In comparison to the other groups, only the female ERα-OE mice survived 100% after the acute phase (without first 24h; n=13-17 per group), however this difference was not statistically significant (p=0.209 vs. female WT, by log-rank test).
Figure 4: ERα-overexpression in cardiomyocytes accelerates both angiogenesis and lymphangiogenesis predominantly in the peri-infarct areas in both sexes. A-B: Representative images of H&E-stained paraffin sections of LV tissues from WT- and ERα-OE mice after MI. ERα-OE mice hearts showed an increased occurrence of vascular-like structures in the peri-infarct area. 20x magnification, scale bar 100µm. C-F: Representative immunofluorescence photographs of LV tissues 2 weeks after sham and MI operation from WT-(C and E) and ERα-OE (D and F) mice with CD31 and LYVE-1staining (scale bar 100 µm). For a better illustration of CD31 and LYVE-1 signals, higher magnification of the LV areas with strongest signals, i.e. in the peri-infarct area, have been shown. CD31-positive vessels (green), LYVE-1 positive vessels (red), nuclei (DAPI, blue). G-H: Quantification of areas of LYVE-1 and CD31 expressing vessels from whole LV cross-sectional areas. Data expressed as mean ± SEM of 3 to 4 animals per group. § for the genotype effect: females: p<0.01 (LYVE-1), p<0.01 (CD31); males: p<0.001 (LYVE-1), p<0.01 (CD31). * for MI effect: females: p<0.001 (LYVE-1), p<0.05 (CD31); males: p<0.05 (LYVE-1). I-J: qRT-PCR analysis of the mRNA levels of Vegf and Lyve-1 in the peri-infarct and infarct areas from WT- and ERα-OE mice. Data expressed as mean ± SEM of 5 to 6 animals per group. § for the genotype effect for each gene: females: p<0.05 (Vegf) and p<0.01 (Lyve-1); males: p<0.05 (Vegf) and 0.001 (Lyve-1).

Figure 5: Phosphorylation level of JNK (pJNK) is increased in only female ERα-OE mice hearts. Representative Western blots (top) and bar graph(bottom) representing the quantitative Western blot analysis of pJNK in LV tissues from female and male WT and ERα-OE mice. Data are expressed as ratio of pJNK to JNK expression. Bars represent the mean ± SEM of 7 to 8 animals per group. § for genotype effect: p<0.01.
cardiomyocytes accelerates both angio genesis and lymphangiogenesis predominantly in the peri-infarct and infarct areas in both sexes.

ERα induces the phosphorylation of JNK signaling pathway only in female hearts after myocardial infarction

JNK1/3 is known as a positive regulator of angiogenic process [32,33]. Western blot analysis of LV extracts from both female and male WT- and ERα-OE mice showed that the phosphorylation level of JNK was significantly increased only in female ERα-OE mice hearts after MI (Figure 5).

ERα attenuates collagen deposition after myocardial infarction only in female hearts

We next determined the effects of ERα overexpression on Col I and Col III gene expression and Col deposition in the hearts of ERα-OE and WT-mice after MI. Expression of Col I and III were significantly increased in the hearts of both female and male WT-mice after MI, but not changed in ERα-OE mice (Figures 6A and 6B). Of note, female mice with ERα-OE expressed significant less Col I and III than female WT-mice after MI. Collagen staining of mid-LV sections from female and male WT- and ERα-OE mice showed significant increase of collagen deposition in all animals (Figure 6C). However, in line with the diminished Col I and III expression, hearts of female ERα-OE mice showed significantly less collagen deposition after MI, compared with female WT-mice (Figure 6C). Overall, ERα overexpression is associated with less fibrosis in female hearts, suggesting that the female hearts are less susceptible to MI-induced remodelling.

Discussion

In this study, we present novel insights into mechanisms that account for the ERα-dependent myocardial protection against myocardial injury, with more beneficial effects in female hearts. Using transgenic mice with a cardiomyocyte-specific ERα overexpression, we first demonstrated that this was associated with an increase of LVM consistent with the increase of cardiomyocyte length at the basal level in both female and male mice. After MI, the cardiomyocyte-specific ERα-OE inhibited changes in LV-volumes and wall thickness only in female mice. These beneficial effects in female ERα-OE hearts were associated with increased angiogenesis and lymphangiogenesis, attenuated ventricular fibrosis and enhanced JNK phosphorylation.

Our study indicates that in the female sex, ERα in cardiomyocytes may have a therapeutic potential in the treatment of ischemic heart disease, leading to more efficient cardiac repair after ischemic injury.

Effects of ERα overexpression on the heart

To address the effect of ERα more precisely on cardiomyocyte following cardiac injury, we generated mice with a constitutive overexpression of ERα in cardiomyocytes. This unique model allows obtaining new insights into ERα mediated Cardioprotective mechanisms. The constitutive cardiomyocyte-specific ERα overexpression resulted in myocardial hypertrophy, associated with higher LVM, increased ventricular volumes, greater cardiomyocyte length, no fibrosis and augmented expression of hypertrophy-associated genes Nppa and Nppb and Myh7/Mhy6 ratio in both sexes at basal level. These are characteristics of an eccentric type of physiological hypertrophy, and have been observed in hearts during pregnancy or in the athlete hearts after endurance training [34-37]. The observed effects in our study may be due to direct effects of ERα as a transcription factor through the regulation of expression of hypertrophy-target genes, or indirect due to hemodynamic alterations. We demonstrated in this study a higher phosphorylation of ERα at Ser118, essential for transcriptional activation [38], as well as a greater translocation of ERα in the nuclei of ERα-OE mice cardiomyocytes, pointing to the functional role of ERα as a transcription factor in this model. Additionally, in a previous study we showed that the expression of hypertrophy-associated genes Nppa, α-actinin and Cx43 are increased by E2-induced activation of ERα in a human cardiomyocyte-like cell line AC16 cells [39]. Therefore, the higher expression and activation of ERα could be an explanation for the increased expression of hypertrophy-associated genes in ERα-OE mice. It is also conceivable that the higher expression of Nppa, Nppb and Myh7 in the LV of ERα-OE is in response to increased cardiomyocyte stretch due to increased cardiomyocyte length, as reported elsewhere [40-43].

Effects of ERα overexpression following myocardial infarction

Following MI, hearts of female ERα-OE mice did not exhibit accelerated post-infarct remodelling. Compared to WT and male ERα-OE mice, in female ERα-OE hearts systolic and diastolic volumes were not increased and LV wall thickness not significantly decreased after MI. These phenomena may lead to reduced wall stress in female ERα-OE hearts after MI, thus attenuating the adverse consequences of remodelling.

Table 1: Morphological and echocardiographic parameters 2 weeks after sham and MI surgery in female and male WT- and ERα-OE mice.

| Genotype | WT-mice | ERα-OE mice |
|----------|---------|-------------|
|          | Female  | Male        | Female  | Male        |
| Treatment | Sham    | MI          | Sham    | MI          |
| BW [g]    | 22.03 ± 0.52 | 21.48 ± 0.54 | 28.17 ± 0.60 | 28.58 ± 0.78 |
| TL [mm]   | 16.32 ± 0.15  | 16.35 ± 0.16  | 16.86 ± 0.09  | 16.81 ± 0.16  |
| LVM [mg]  | 94.69 ± 2.97  | 90.94 ± 1.99  | 113.97 ± 2.10 | 121.10 ± 4.31 |
| LV/LV [mg/mm] | 5.19 ± 0.17  | 5.57 ± 0.14  | 6.76 ± 0.13  | 7.20 ± 0.24  |
| LVW [mm]  | 0.63 ± 0.02  | 0.57* ± 0.01  | 0.71* ± 0.01 | 0.62* ± 0.01  |
| LVVol,d [µl] | 40.90 ± 1.81 | 67.43* ± 6.64 | 52.71 ± 2.14 | 95.77* ± 8.95 |
| LVVol,s [µl] | 14.01 ± 1.26 | 47.51* ± 6.14 | 19.98 ± 1.18 | 67.74* ± 10.72 |
| HR [bpm]  | 480.3 ± 14.80 | 525.5 ± 12.38 | 495.8 ± 10.12 | 515.8 ± 12.65 |
| LVSV [µl] | 24.89 ± 3.61 | 31.23 ± 3.38 | 31.23 ± 3.14 | 31.23 ± 3.84 |
| LVCO [ml/min] | 13.11 ± 0.86 | 10.41 ± 0.64 | 14.26 ± 0.19 | 29.18 ± 3.20 |
| Infarctsize (%) | 35.23 ± 3.38 | 35.23 ± 3.38 | 35.23 ± 3.38 | 35.23 ± 3.38 |

Data are means ± SEM. MI: Myocardial Infarction; Sham: sham operation; F: female; M: male; n: number of animals; BW: body weight; TL: tibia length; HW: heart weight; LVM: left ventricular (LV) mass; LVW: LV wall thickness; LVVol,d: LV diastolic volume; LVVol,s: LV systolic volume; HR: heart rate; LVS V: LV stroke volume; LVCO: LV cardiac output. All data are shown as Mean ± SEM. *p<0.05 MI vs. sham, 5p<0.05 ERα-OE vs. WT.
With this study, we also provide evidence that cardiomyocyte-specific ERα overexpression facilitates angiogenesis and lymphangiogenesis (new blood and lymphatic vessels sprouting from pre-existing vessels) in the heart in response to MI in both sexes. In this respect, the mRNA expression of angiogenesis and lymphangiogenesis markers Vegf and Lyve-1, and the area of both CD31- and LYVE-1 expressing vessels were significantly increased predominately in the peri-infarct and to lesser extent in the infarct area of the hearts from ERα-OE mice. This indicates that ERα induces angiogenesis and lymphangiogenesis in the heart after MI. Our data are in accordance with other studies which provide evidence that the known pro-angiogenic properties of E2 [44-48] are mainly mediated by ERα in different tissues under normal and pathologic conditions. Angiogenesis is impaired in ERKO mice [49-52] or upon ER antagonist-treatment [53] and is increased by ERα-agonist [54]. An important molecule that controls angiogenesis and lymphangiogenesis in the healing area after MI is VEGF [55-57], which can be regulated by E2 in different organs, including the myocardium [44,47,58,59]. It has been speculated that this estrogenic effect is most probably mediated through activation of ERα, since the absence or deficiency of functional ERα leads to the reduction of expression level of Vegf and reduced coronary capillary density in female mouse hearts [60,61]. Additionally, it has been reported that E2-activated ER inhibits the expression and secretion of Thrombospondin-1, a negative regulator of angiogenesis, in human umbilical vein endothelial cells through activation of JNK in a non-genomic manner [62]. In line with this data we observed an increased phosphorylation of JNK (pJNK) in female ERα-OE cardiomyocytes. The E2/ERα mediated JNK-activation in this study could be either mediated by increased expression of cardiomyocytes-derived VEGF in a paracrine manner, as shown in vascular endothelial cells [32,33], or demonstrates an additional mechanism independent of VEGF in female ERα-OE mice heart.

So far, it is not clear to what extent ERα affects the lymphangiogenesis in the heart after MI. To the best of our knowledge, this study is the first work that shows the involvement of ERα in the enhancement of lymphangiogenesis after MI.

Both angiogenesis and lymphangiogenesis are of clinical interest because of their important roles in wound healing and tissue repair. Angiogenesis advances delivery of both oxygen and energy substrates in peri-infarct and infarct area, and has the potential to salvage ischemic myocardium at early stages after MI [63]. Lymphangiogenesis...
cardioprotective function, and attenuation of cardiac remodeling in a paracrine fashion 
and functions, and attenuation of cardiac remodeling in a paracrine fashion in response to cardiac ischemic injury.

Acknowledgements

We thank Arne Kuehne, Britta Fielitz and Petra Domaing for excellent technical support. This work was supported by the Deutsche Forschungsgemeinschaft (GRK 754, FOR1054 to VRZ and SM); the German Center for Cardiovascular Research (DZHK) to VRZ; and National Cancer Institute (NIH grants R01 CA112176 and P30 CA051008 (Animal Shared Resource) to PAF.

References

1. Reglitz-Zagrosek V (2006) Therapeutic implications of the gender-specific aspects of cardiovascular disease. Nat Rev Drug Discov 5: 425-438.
2. Beer S, Reincke M, Kral M, Lie SZ, Steinhauer S, et al. (2002) Susceptibility to myocardial infarction. J Am Soc Echocardiogr 15: 601-609.
3. Vornehm ND, Wang M, Abarbanell A, Herrmann J, Weil B, et al. (2009) Acute receptor-beta agonist improves myocardial recovery. Surgery 146: 145-154.
4. Kolodgie FD, Farb A, Litovsky SH, Narula J, Jeffers LA, et al. (1997) Myocardial protection of contractile function after global ischemia by physiologic estrogen replacement in the ovariectomized rat. J Mol Cell Cardiol 29: 2403-2414.
5. Lee TM, Lin MS, Chou TF, Tsai CH, Chang NC (2004) Adjunctive 17beta-estriol administration reduces infarct size by altered expression of canine myocardial connexin43 protein. Cardiovasc Res 63: 109-117.
6. Nikolic I, Liu D, Bell JA, Collins J, Steenbergen C, et al. (2007) Treatment with an estrogen receptor-beta-selective agonist is cardioprotective. J Mol Cell Cardiol 42: 769-780.
7. Mahmoodzadeh S, Dworatzek E, Fritschka S, Pham TH, Reglitz-Zagrosek V (2010) 17beta-Estradiol inhibits matrix metalloproteinase-2 transcription via MAP kinase in fibroblasts. Cardiovasc Res 85: 719-728.
8. Mahmoodzadeh S, Eder S, Nordmeyer J, Ehrer E, Huber O, et al. (2006) Estrogen receptor alpha up-regulation and redistribution in human heart failure. FASEB J 20: 926-934.
9. Nordmeyer J, Eder S, Mahmoodzadeh S, Martus P, Fielitz J, et al. (2004) Upregulation of myocardial estrogen receptors in human aortic stenosis. Circulation 113: 3270-3275.
10. Rogero AB, Eghbali M, Minosyan TY, Tang G, Toro L, et al. (2006) Heart estrogen receptor alpha: distinct membrane and nuclear distribution patterns and regulation by estrogen. J Mol Cell Cardiol 41: 496-510.
11. Osudio DW, Kearney M, Kim EJ, Jekanowski J, Isner JM (1994) Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation 98: 1501-1510.
12. Post WS, Goldschmidt-Clermont PJ, Wilhide CC, Heldman AW, Sussman MS, et al. (1999) Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovasc Res 43: 985-991.
13. Wang M, Crisostomo P, Wairaku GM, Meldrum DR (2006) Estrogen receptor-alpha mediates acute myocardial protection in females. Am J Physiol Heart Circ Physiol 290: H2204-2209.
14. Zhai P, Eurell TE, Cooke PS, Lubahn DB, Gross DR (2000) Myocardial ischemia-reperfusion injury in estrogen receptor-alpha knockout and wild-type mice. Am J Physiol Heart Circ Physiol 278: H1640-1647.
15. Booth EA, Obeid NR, Lucchesi BR (2005) Activation of estrogen receptor-alpha protects the in vivo rabbit heart from ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 289: H2039-2047.
16. Novotny JL, Simpson AM, Tomiwcik NJ, Lancaster TS, Kozicki DH (2009) Rapid estrogen receptor-alpha activation improves ischemic tolerance in aged female rats through a novel protein kinase C epsilon-dependent mechanism. Endocrinology 150: 889-896.
17. Vormehr ND, Wang M, Abarbanell A, Herrmann J, Well B, et al. (2009) Acute postischemic treatment with estrogen receptor-alpha agonist or estrogen receptor-beta agonist improves myocardial recovery. Surgery 146: 145-154.
18. Takemura G, Fujihara H (2004) Role of apoptosis in remodeling after myocardial infarction. Pharmacol Ther 104: 1-16.
19. Kanno S, Lerner DL, Schuessler RB, Betsuya Y, Yamada KA, et al. (2002) Echocardiographic evaluation of ventricular remodeling in a mouse model of myocardial infarction. J Am Soc Echocardiogr 15: 601-609.
20. Peltzhoth D, Lossie J, Keller S, Werner S, Haase H, et al. (2011) Human essential myosin light chain isoforms revealed distinct myosin binding, sarcomeric sorting, and inotropic activity. Cardiovasc Res 90: 513-520.
21. Witt H, Schubert C, Jaekel J, Flieger D, Penkalla A, et al. (2008) Sex-specific pathways in early cardiac response to pressure overload in mice. J Mol Med (Berl) 86: 1013-1024.
32. Uchida C, Gee E, Ispasovic E, Haas TL (2008) JNK as a positive regulator of angiogenic potential in endothelial cells. Cell Biol Int 32: 769-776.
33. Wu G, Luo J, Rana JS, Laham R, Seltke FW, et al. (2008) Involvement of COX-2 in VEGF-induced angiogenesis via P38 and JNK pathways in vascular endothelial cells. Cardiovasc Res 69: 512-519.
34. Dom GW 2nd (2007) The fuzzy logic of physiological cardiac hypertrophy. Hypertension 49: 962-970.
35. Eghbali M, Deva R, Alioua A, Minosyan TY, Ruan H, et al. (2005) Molecular and functional signature of heart hypertrophy during pregnancy. Circ Res 96: 1208-1216.
36. Fernandes T, Soci UP, Oliveira EM (2011) Eccentric and concentric cardiac hypertrophy induced by exercise training: microRNAs and molecular determinants. Braz J Med Biol Res 44: 836-847.
37. Zhang Y, Novak K, Kaufman S (1995) Atrial natriuretic factor release during pregnancy in rats. J Physiol 488: 509-514.
38. Lannigan DA (2003) Estrogen receptor phosphorylation. Steroids 68: 1-9.
39. Mahmoodzadeh S, Pham TH, Kuhne A, Fietz B, Dworatzek E, et al. (2012) 17beta-Estradiol-interaction of ERs with NPPA regulates gene expression in cardiomyocytes. Cardiovasc Res 96: 411-421.
40. Elmers LJ, Knowles JW, Kim HS, Smithies O, Maeda N, et al. (2002) Ventricular expression of natriuretic peptides in Npr1(-/-) mice with cardiac hypertrophy and fibrosis. Am J Physiol Heart Circ Physiol 283: H707-714.
41. Holtwick R, van Eickels M, Skryabin BV, Baba HA, Burbak A, et al. (2003) Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J Clin Invest 111: 1399-1407.
42. Molkentin JD, Dom GW 2nd (2001) Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol 63: 391-426.
43. Wagner N, Jehl-Pietri C, Lopez P, Murdaca J, Giordano C, et al. (2009) Peroxisome proliferator-activated receptor beta stimulation induces rapid cardiac growth and angiogenesis via direct activation of calcineurin. Cardiovasc Res 83: 61-71.
44. Jesmin S, Sakuma I, Hattori Y, Kitabatake A (2002) In vivo estrogen manipulations on coronary capillary network and angiogenic molecule expression in middle-aged female rats. Arterioscler Thromb Vasc Biol 22: 1591-1597.
45. Losordo DW, Isner JM (2001) Estrogen and angiogenesis: A review. Arterioscler Thromb Vasc Biol 21: 8-12.
46. Miller VM, Duckles SP (2008) Vascular actions of estrogens: functional implications. Pharmacol Rev 60: 210-241.
47. Morales DE, McGowan KA, Grant DS, Maheshwari S, Bhartiya D, et al. (1995) Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model. Circulation 91: 755-763.
48. Urbich C, Dimmeler S (2005) Risk factors for coronary artery disease, circulating endothelial progenitor cells, and the role of HMG-CoA reductase inhibitors. Kidney Int 67: 1672-1676.
49. Ardetl AA, McCullough LD, Korach KS, Wang MM, Munzenmaier DH, et al. (2005) Estradiol regulates angiopoietin-1 mRNA expression through estrogen receptor-alpha in a rodent experimental stroke model. Stroke 36: 337-341.
50. Brouchet L, Krust A, Dupont S, Chambon P, Bayard F, et al. (2001) Estradiol accelerates reendothelialization in mouse carotid artery through estrogen receptor-alpha but not estrogen receptor-beta. Circulation 103: 423-428.
51. Johs A, Freay AD, Fraser W, Korach KS, Rubanyi GM (1996) Dissipation of estrogen receptor gene prevents 17 beta estradiol-induced angiogenesis in transgenic mice. Endocrinology 137: 4511-4513.
52. Pare G, Krust A, Karas RH, Dupont S, Aronovitz M, et al. (2002) Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury. Circ Res 90: 1087-1092.
53. Gagliardi A, Collins DC (1993) Inhibition of angiogenesis by antiestrogens. Cancer Res 53: 533-535.
54. Zaitseva M, Yue DS, Katzellenbogen JA, Rogers PA, Gargett CE (2004) Estragon receptor-alpha agonists promote angiogenesis in human myometrial microvascular endothelial cells. J Soc Gynecol Invest 11: 529-535.
55. Banai S, Shevki D, Pinson A, Chandra M, Lazaroavici G, et al. (1994) Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: implications for coronary angiogenesis. Cardiovasc Res 28: 1176-1179.
56. Hobein A, Landuyt B, Hightey MS, Wildiers H, Van Ostember ST, et al. (2004) Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 56: 549-580.
57. Ishikawa Y, Akishima-Fukasawa Y, Ito K, Akasaka Y, Tanaka M, et al. (2007) Lymphangiogenesis in myocardial remodelling after infarction. Histopathology 51: 345-353.
58. Buteau-Lozano H, Ancelin M, Lardeux B, Milanini J, Perrot-APlanat M (2002) Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta. Cancer Res 62: 4977-4984.
59. Gargett CE, Zaitseva M, Buccak K, Chu S, Fuller PJ, et al. (2002) 17Beta-estradiol up-regulates vascular endothelial growth factor receptor-2 expression in human myometrial microvascular endothelial cells: role of estrogen receptor-alpha and -beta. J Clin Endocrinol Metab 87: 4341-4349.
60. Hamada H, Kim MK, Iwakura A, Li M, Thorne T, et al. (2006) Estrogen receptors alpha and beta mediate contribution of bone marrow-derived endothelial progenitor cells to functional recovery after myocardial infarction. Circulation 114: 2261-2270.
61. Jesmin S, Mowa CN, Sultana SN, Shimpoji N, Togashi H, et al. (2010) VEGF signaling is disrupted in the hearts of mice lacking estrogen receptor alpha. Eur J Pharmacol 641: 168-178.
62. Sengupta K, Banerjee S, Saxena NK, Banerjee SK (2004) Thrombospondin-1 disrupts estrogen-induced endothelial cell proliferation and migration and its expression is suppressed by estradiol. Mol Cancer Res 2: 150-158.
63. Cochian C, Channon KM, Silvestre JS (2013) Angiogenesis in the infarcted myocardium. Antioxid Redox Signal 18: 4341-4349.
64. Cui Y (2010) The role of lymphatic vessels in the heart. Pathophysiology 17: 307-314.
65. Laine GA, Allen SJ (1991) Left ventricular myocardial edema. Lymph flow, interstitial fibrosis, and cardiac function. Circ Res 68: 1713-1721.
66. Park JH, Yoon JY, Ko SM, Jin SA, Kim JH, et al. (2011) Endothelial progenitor cell transplantation decreases lymphangiogenesis and adverse myocardial remodeling in a mouse model of acute myocardial infarction. Exp Mol Med 43: 479-485.
67. Davis KL, Laine GA, Geisser HJ, Mehlhorn U, Brennan M, et al. (2000) Effects of myocardial edema on the development of myocardial interstitial fibrosis. Microcirculation 7: 289-290.
68. Westphal C, Schubert C, Prell K, Penkalla A, Fliegner D, et al. (2012) Effects of estrogen, an ERα agonist and raloxifene on pressure overload induced cardiac hypertrophy. PLoS One 7: e50802.